Effect of Linagliptin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients with Persistent Prediabetes After Metformin and Lifestyle

Overview

Journal Sci Rep

Specialty Science

Date 2021 Apr 23

PMID 33888772

Citations 4

Authors

Mildred Fatima de la Luz Alvarez-Canales

Sara Stephania Salazar-Lopez

Diana Farfan-Vazquez

Yosceline Estrella Martinez-Lopez

Jessica Noemi Gonzalez-Mena

Lilia Marisela Jimenez-Ceja

Katya Vargas-Ortiz

Maria Lola Evia-Viscarra

Maria Luisa Montes de Oca-Loyola

Franco Folli

Alberto Aguilar-Garcia

Rodolfo Guardado-Mendoza

Affiliations

Soon will be listed here.

Abstract

The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind randomized clinical trial with 6 months of follow-up was performed in patients with persistent IGT after 12 months of treatment with metformin and lifestyle; patients were randomized to continue with metformin 850 mg twice daily (M group, n = 12) or linagliptin/metformin 2.5/850 mg twice daily (LM group, n = 19). Anthropometric measurements were obtained by standard methods and by bioelectrical impedance; glucose was measured by dry chemistry, insulin by chemiluminescence, and pancreatic β-cell function was calculated with the disposition index using glucose and insulin values during oral glucose tolerance test (OGTT) and adjusting by insulin sensitivity. The main outcomes were glucose levels during OGTT and pancreatic β-cell function. Patients in the LM group had a reduction in weight (-1.7 ± 0.6, p < 0.05) and body mass index (BMI, -0.67 ± 0.2, p < 0.05). Glucose levels significantly improved in LM group with a greater reduction in the area under the glucose curve during OGTT (AUCGluc) as compared to the M group (-4425 ± 871 vs -1116 ± 1104 mg/dl/120 min, p < 0.001). Pancreatic β-cell function measured with the disposition index, improved only in LM group (2.3 ± 0.23 vs 1.7 ± 0.27, p 0.001); these improvements persisted after controlling for OGTT glucose levels. The differences in pancreatic β-cell function persisted also after pairing groups for basal AUCGluc. The addition of linagliptin to patients with persistent IGT after 12 months of treatment with metformin and lifestyle, improved glucose levels during OGTT and pancreatic β-cell function after 6 months of treatment.Trial registration: Clinicaltrials.gov with the ID number NCT04088461.

Citing Articles

Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.

Martinez-Lopez Y, Neri-Rosario D, Esquivel-Hernandez D, Padron-Manrique C, Vazquez-Jimenez A, Sanchez-Castaneda J Sci Rep. 2024; 14(1):9678.

PMID: 38678119 PMC: 11055900. DOI: 10.1038/s41598-024-60081-y.

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.

Haddad F, Dokmak G, Bader M, Karaman R Life (Basel). 2023; 13(4).

PMID: 37109541 PMC: 10144237. DOI: 10.3390/life13041012.

Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial.

Gabriel R, Boukichou-Abdelkader N, Gilis-Januszewska A, Makrilakis K, Gomez-Huelgas R, Kamenov Z J Clin Med. 2023; 12(5).

PMID: 36902821 PMC: 10004435. DOI: 10.3390/jcm12052035.

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes.

Chong S, Sukor N, Robert S, Ng K, Kamaruddin N Front Endocrinol (Lausanne). 2022; 13:1012412.

PMID: 36267570 PMC: 9576919. DOI: 10.3389/fendo.2022.1012412.

References

Utzschneider K, Prigeon R, Faulenbach M, Tong J, Carr D, Boyko E . Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2008; 32(2):335-41. PMC: 2628704. DOI: 10.2337/dc08-1478. View

Abdul-Ghani M, Jenkinson C, Richardson D, Tripathy D, DeFronzo R . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006; 55(5):1430-5. DOI: 10.2337/db05-1200. View

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

Bergman M, Abdul-Ghani M, DeFronzo R, Manco M, Sesti G, Fiorentino T . Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract. 2020; 165:108233. PMC: 7977482. DOI: 10.1016/j.diabres.2020.108233. View

Ahren B, Foley J . Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016; 59(5):907-17. DOI: 10.1007/s00125-016-3899-2. View

Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C . High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes. 2001; 50(6):1290-301. DOI: 10.2337/diabetes.50.6.1290. View

Guardado-Mendoza R, Salazar-Lopez S, Alvarez-Canales M, Farfan-Vazquez D, Martinez-Lopez Y, Jimenez-Ceja L . The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. Metabolism. 2019; 104:154054. DOI: 10.1016/j.metabol.2019.154054. View

Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanne-Parikka P . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18):1343-50. DOI: 10.1056/NEJM200105033441801. View

le Roux C, Astrup A, Fujioka K, Greenway F, Lau D, Van Gaal L . 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017; 389(10077):1399-1409. DOI: 10.1016/S0140-6736(17)30069-7. View

10.

Nahon K, Doornink F, Straat M, Botani K, Martinez-Tellez B, Abreu-Vieira G . Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. Diabetologia. 2018; 61(11):2386-2397. PMC: 6182651. DOI: 10.1007/s00125-018-4716-x. View

11.

Perreault L, Temprosa M, Mather K, Horton E, Kitabchi A, Larkin M . Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014; 37(9):2622-31. PMC: 4140157. DOI: 10.2337/dc14-0656. View

12.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

13.

Alegre-Diaz J, Herrington W, Lopez-Cervantes M, Gnatiuc L, Ramirez R, Hill M . Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med. 2016; 375(20):1961-1971. PMC: 5215048. DOI: 10.1056/NEJMoa1605368. View

14.

Hernandez-Avila M, Romieu I, Parra S, Hernandez-Avila J, Madrigal H, Willett W . Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex. 1998; 40(2):133-40. DOI: 10.1590/s0036-36341998000200005. View

15.

Faerch K, Torekov S, Vistisen D, Johansen N, Witte D, Jonsson A . GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes. 2015; 64(7):2513-25. DOI: 10.2337/db14-1751. View

16.

Abdul-Ghani M, Tripathy D, DeFronzo R . Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006; 29(5):1130-9. DOI: 10.2337/diacare.2951130. View

17.

Prattichizzo F, de Candia P, De Nigris V, Nicolucci A, Ceriello A . Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. Metabolism. 2020; 110:154308. DOI: 10.1016/j.metabol.2020.154308. View

18.

Guardado-Mendoza R, Chavez A, Jimenez-Ceja L, Hansis-Diarte A, DeFronzo R, Folli F . Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus. Acta Diabetol. 2016; 54(1):53-61. DOI: 10.1007/s00592-016-0904-7. View

19.

. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007; 24(2):137-44. PMC: 2267935. DOI: 10.1111/j.1464-5491.2007.02043.x. View

20.

Wang Z, Xu D, Huang L, Zhang T, Wang J, Chen Q . Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes. Diabetes Res Clin Pract. 2017; 130:77-85. DOI: 10.1016/j.diabres.2017.05.012. View